Neuroplasticity Enhancement Devices Market Size, Share, Trends, Industry Analysis Report: By Product Type [Transcranial Magnetic Stimulation (TMS) Devices, Transcranial Direct Current Stimulation (tDCS) Devices, Electroencephalogram (EEG)-Based Devices, and Others], Application, End User, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) – Market Forecast, 2025–2034
- Published Date:Mar-2025
- Pages: 129
- Format: PDF
- Report ID: PM5416
- Base Year: 2024
- Historical Data: 2020-2023
Neuroplasticity Enhancement Devices Market Overview
The global neuroplasticity enhancement devices market size was valued at USD 6.51 billion in 2024. The market is projected to grow from USD 8.26 billion in 2025 to USD 71.40 billion by 2034, exhibiting a CAGR of 27.1 % during 2025–2034.
Neuroplasticity enhancement devices are technologies and tools designed to improve the brain's ability to reorganize itself by forming new neural connections throughout life. These devices and therapies aim to optimize brain function by targeting specific brain regions or neural pathways to stimulate and promote increased function. They help in creating, restoring, improving, or maintaining brain function.
The increasing prevalence of Alzheimer's disease and Parkinson's disease worldwide propels the neuroplasticity enhancement devices market growth. According World Health Organization, the prevalence of Parkinson's disease (PD) has doubled in the past 25 years. Patients and healthcare providers seek technologies that promote neural adaptation and recovery as more people suffer from Alzheimer's disease and Parkinson's disease. Neuroplasticity enhancement devices, such as transcranial magnetic stimulation (TMS) and neurofeedback systems, help strengthen neural connections and compensate for damaged areas of the brain through Alzheimer's disease and Parkinson's disease. Researchers and medical professionals further invest in these tools to slow disease progression, enhance quality of life, and offer noninvasive alternatives to traditional treatments. Therefore, as the prevalence of Alzheimer's disease and Parkinson's disease increases, the demand for neuroplasticity enhancement devices also grows.
The growing advancements in technology boost neuroplasticity enhancement devices market demand. Innovations, such as AI-powered neurofeedback systems and noninvasive brain stimulation techniques, offer precise and personalized brain training. These innovations attract individuals seeking cognitive enhancement, rehabilitation, and mental health improvements. Moreover, healthcare professionals adopt these advanced tools to improve treatment outcomes, thereby fueling the neuroplasticity enhancement devices market development.
Neuroplasticity Enhancement Devices Market Dynamics
Increasing Geriatric Population Globally
Aging naturally reduces the brain's ability to reorganize and form new neural connections. According to WORLD SOCIAL REPORT 2023, the number of people aged 65 years and above worldwide is projected to more than double, rising from 761 million in 2021 to 1.6 billion by 2050. Neuroplasticity-enhancing devices are crucial for maintaining cognitive function and improving quality of life. These devices, which include brain stimulation tools, neurofeedback systems, and cognitive training platforms, help the aging population enhance memory and focus and maintain overall brain health. Therefore, as the elderly population grows, healthcare systems and individuals prioritize preventive and therapeutic solutions to combat age-related cognitive challenges such as memory loss and neurodegenerative diseases. Hence, the increasing geriatric population across the world is driving the neuroplasticity enhancement devices market growth.
Growing Prevalence of Depression Among Young Population
Depression often disrupts neural pathways and impairs brain plasticity, leading to difficulties in emotional regulation, memory, and concentration. Neuroplasticity enhancement devices, such as transcranial magnetic stimulation (TMS) headsets, neurofeedback systems, and cognitive training apps, help restore healthy neural connections. Younger populations are increasingly aware of mental health issues and seeking noninvasive and drug-free alternatives to traditional therapies, driving interest in neuroplasticity enhancement devices. Additionally, as research continues to highlight the link between neuroplasticity and depression, the demand for these devices grows, offering improved emotional and cognitive outcomes among young individuals.
Neuroplasticity Enhancement Devices Market Segmental Insights
Neuroplasticity Enhancement Devices Market Evaluation by Product Type
Based on product type, the neuroplasticity enhancement devices market is segmented into transcranial magnetic stimulation (TMS) devices, transcranial direct current stimulation (tDCS) devices, electroencephalogram (EEG)-based devices, and others. The transcranial magnetic stimulation (TMS) devices segment held the largest neuroplasticity enhancement devices market share in 2024 due to their proven effectiveness in treating neurological and psychiatric disorders. Clinics and hospitals widely adopted TMS devices to manage depression, anxiety, and neurodegenerative conditions. Physicians prefer these devices as they offer noninvasive, targeted brain stimulation with minimal side effects compared to pharmaceutical treatments. Growing research on TMS for cognitive enhancement and stroke rehabilitation strengthened its market position. Patients seeking alternatives to medication increasingly turned to these devices, increasing their demand across healthcare settings. Additionally, regulatory approvals and insurance coverage expansions in several regions boosted its accessibility, making TMS the dominant segment in the market.
Neuroplasticity Enhancement Devices Market Assessment by End User
In terms of end user, the neuroplasticity enhancement devices market is segregated into hospitals & clinics, research institutions & academic centers, home care settings, and others. The hospitals & clinics segment accounted for a major market share in 2024 due to their extensive adoption of advanced brain stimulation and neurofeedback technologies. Healthcare professionals increasingly integrated these devices into treatment plans for neurological disorders, mental health conditions, and post-stroke rehabilitation. The availability of skilled professionals in clinical settings ensured safe and effective application, making hospitals and specialized clinics the preferred choice for patients. Rising cases of depression, Alzheimer’s disease, and Parkinson’s disease fueled the demand for evidence-based neuroplasticity treatments, further strengthening the segment’s dominance. Government funding, insurance reimbursements, and expanding clinical research on noninvasive brain stimulation also contributed to the segment’s dominant share.
The home care settings segment is projected to hold a dominant share in the coming years as individuals seek convenient, cost-effective solutions for cognitive enhancement and neurological rehabilitation. Advancements in wearable technology and smartphone-integrated brain stimulation devices allow users to monitor and improve their brain function from home. Patients recovering from strokes, individuals managing chronic neurological conditions, and healthy users interested in cognitive optimization increasingly turn to portable neurotechnology for daily use. The rising demand for remote healthcare solutions and the shift toward personalized treatment further accelerate the growth of the segment.
Neuroplasticity Enhancement Devices Market Regional Analysis
By region, the report provides the neuroplasticity enhancement devices market insights into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the neuroplasticity enhancement devices market share in 2024 due to its strong healthcare infrastructure, high adoption of advanced neurotechnology, and increasing prevalence of neurological disorders. The presence of major medical device companies, high research investments, and widespread awareness of neuroplasticity benefits fueled market growth in the region. The rising number of patients seeking noninvasive brain stimulation for depression, cognitive enhancement, and neurorehabilitation further strengthened the demand for neuroplasticity enhancement devices in the region. The US dominated the North American market, driven by its well-established healthcare system, favorable reimbursement policies, and continuous innovations in brain stimulation technologies. Regulatory approvals from agencies such as the FDA also played a crucial role in accelerating product adoption across clinical and home-care settings.
The Asia Pacific neuroplasticity enhancement devices market is expected to grow in the coming years, owing to rapid urbanization, and increasing healthcare expenditures. Countries such as China, Japan, and India are witnessing a surge in the prevalence of neurological disorders due to aging populations and lifestyle-related cognitive decline, thereby driving demand for neuroplasticity enhancement devices. Expanding access to neurostimulation therapies, rising investments in neuroscience research, and government initiatives supporting mental health solutions contribute to the Asia Pacific neuroplasticity enhancement devices market expansion. Furthermore, China is expected to lead the Asia Pacific market during the forecast period, propelled by its advancements in medical technology, strong manufacturing capabilities, and increasing focus on AI-driven brain-computer interface applications.
Neuroplasticity Enhancement Devices Market – Key Players & Competitive Analysis Report
Prominent market players are investing heavily in research and development to expand their offerings, which will boost the neuroplasticity enhancement devices market development in the coming years. These market participants are undertaking a variety of strategic activities to expand their global footprint, with important market developments, including innovative launches, international collaborations, higher investments, and mergers and acquisitions between organizations.
The neuroplasticity enhancement devices market is fragmented, with the presence of numerous global and regional market players. A few major players in the market include BioSerenity; Blackrock Neurotech; BrainCo Inc.; BrainsWay; Ceribell, Inc.; EMOTIV; Flow Neuroscience; Neurable; Neuralink; NeuroPace, Inc.; Paradromics; and Synchron.
BrainsWay is a global medical technology company that develops noninvasive neurostimulation treatments for various mental health disorders. The treatments of the company utilize Deep Transcranial Magnetic Stimulation (Deep TMS), a platform that aims to improve health and transform lives. BrainsWay's Deep TMS is FDA-cleared for treating major depressive disorder (including anxious depression), obsessive-compulsive disorder (OCD), and smoking addiction. The company is dedicated to advancing neuroscience through clinical evidence, with ongoing trials for psychiatric, neurological, and addiction disorders. The company's Deep TMS treatment is based on the concept of neuroplasticity, the brain's ability to adapt its structure and function. Deep TMS aims to stabilize and regulate neural activity, relieving symptoms of mental health conditions.
Flow Neuroscience is a Swedish medical device company that develops a novel treatment for depression, combining an easy-to-use brain stimulation headset with a personalized mobile app. The company was founded by a clinical psychologist and an engineer with a focus on science, empowerment, and accessibility. Flow's primary product is a medical-grade headset that delivers transcranial Direct Current Stimulation (tDCS). The tDCS headset works by delivering a weak electrical current to brain areas, helping to restore normal brain activity and alleviate depression symptoms. Flow Neuroscience is dedicated to providing medication-free treatment solutions for depression. Their device has regulatory approval in the EU and UK and is available in the EU, Norway, Hong Kong, and Brazil. The company is also targeting FDA approval in the US.
List of Key Companies in Neuroplasticity Enhancement Devices Market
- BioSerenity
- Blackrock Neurotech
- BrainCo Inc.
- BrainsWay
- Ceribell, Inc.
- EMOTIV
- Flow Neuroscience
- Neurable
- Neuralink
- NeuroPace, Inc.
- Paradromics
- Synchron
Neuroplasticity Enhancement Devices Industry Developments
August 2024: UC Davis Health introduced a new brain-computer interface (BCI) that translates brain signals into speech with up to 97% accuracy, the most accurate system of its kind.
January 2024: Magstim, a company involved in developing advanced solutions to study and treat the brain, announced that it received FDA clearance for its Horizon 3.0 transcranial magnetic stimulation (TMS) device with StimGuide Pro for treating patients affected by depressive or obsessive-compulsive conditions.
January 2024: BrainsWay, a global company in advanced noninvasive neurostimulation treatments for mental health disorders, launched two feasibility studies to investigate a new type of transcranial magnetic stimulation (TMS) system for stroke and obsessive-compulsive disorder (OCD).
Neuroplasticity Enhancement Devices Market Segmentation
By Product Type Outlook (Revenue, USD Billion, 2020–2034)
- Transcranial Magnetic Stimulation (TMS) Devices
- Transcranial Direct Current Stimulation (tDCS) Devices
- Electroencephalogram (EEG)-Based Devices
- Others
By Application Mode Outlook (Revenue, USD Billion, 2020–2034)
- Cognitive Enhancement
- Stroke & Traumatic Brain Injury Recovery
- Mental Health & Neurological Disorders
- Learning & Memory Improvement
- Others
By End User Outlook (Revenue, USD Billion, 2020–2034)
- Hospitals & Clinics
- Research Institutions & Academic Centers
- Home Care Settings
- Others
By Regional Outlook (Revenue, USD Billion, 2020–2034)
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
Neuroplasticity Enhancement Devices Market Report Scope
|
Report Attributes |
Details |
|
Market Size Value in 2024 |
USD 6.51 Billion |
|
Revenue Forecast in 2025 |
USD 8.26 Billion |
|
Revenue Forecast by 2034 |
USD 71.40 Billion |
|
CAGR |
27.1% from 2025 to 2034 |
|
Base Year |
2024 |
|
Historical Data |
2020–2023 |
|
Forecast Period |
2025–2034 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2025 to 2034 |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Regional Scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, regions, and segmentation. |
FAQ's
The global neuroplasticity enhancement devices market size was valued at USD 6.51 billion in 2024 and is projected to grow to USD 71.40 billion by 2034.
The global market is projected to register a CAGR of 27.1 % during the forecast period.
North America held the largest share of the global market in 2024.
A few of the key players in the market are BioSerenity; Blackrock Neurotech; BrainCo Inc.; BrainsWay; Ceribell, Inc.; EMOTIV; Flow Neuroscience; Neurable; Neuralink; NeuroPace, Inc.; Paradromics; and Synchron.
The home care settings segment is expected to grow during the forecast period.
© 2025 Polaris Market Research and Consulting. All rights reserved
